- Home
- QUAD vs CDXC Comparison
QUAD vs CDXC Comparison
Compare QUAD & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUAD
- CDXC
- Stock Information
- Founded
- QUAD 1971
- CDXC 1999
- Country
- QUAD United States
- CDXC United States
- Employees
- QUAD N/A
- CDXC N/A
- Industry
- QUAD Publishing
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- QUAD Consumer Discretionary
- CDXC Health Care
- Exchange
- QUAD Nasdaq
- CDXC Nasdaq
- Market Cap
- QUAD 408.6M
- CDXC 449.5M
- IPO Year
- QUAD 2010
- CDXC N/A
- Fundamental
- Price
- QUAD $6.00
- CDXC $5.42
- Analyst Decision
- QUAD Strong Buy
- CDXC Strong Buy
- Analyst Count
- QUAD 2
- CDXC 2
- Target Price
- QUAD $10.15
- CDXC $8.00
- AVG Volume (30 Days)
- QUAD 335.2K
- CDXC 338.3K
- Earning Date
- QUAD 02-18-2025
- CDXC 03-05-2025
- Dividend Yield
- QUAD 3.76%
- CDXC N/A
- EPS Growth
- QUAD N/A
- CDXC N/A
- EPS
- QUAD N/A
- CDXC 0.02
- Revenue
- QUAD $2,672,200,000.00
- CDXC $91,668,000.00
- Revenue This Year
- QUAD N/A
- CDXC $18.64
- Revenue Next Year
- QUAD N/A
- CDXC $20.72
- P/E Ratio
- QUAD N/A
- CDXC $275.46
- Revenue Growth
- QUAD N/A
- CDXC 9.95
- 52 Week Low
- QUAD $4.06
- CDXC $1.48
- 52 Week High
- QUAD $9.13
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- QUAD 40.04
- CDXC 41.57
- Support Level
- QUAD $6.57
- CDXC $5.38
- Resistance Level
- QUAD $8.04
- CDXC $6.06
- Average True Range (ATR)
- QUAD 0.64
- CDXC 0.22
- MACD
- QUAD -0.06
- CDXC 0.00
- Stochastic Oscillator
- QUAD 1.92
- CDXC 5.88
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.